To model clinical resistance to CDK4/6i therapy preclinically, we exposed estrogen-independent, CDK4/6i-sensitive breast cancer cell lines described above to increasing concentrations of each of the three CDK4/6i over a period of 6–12 months. The gene discussed is CDK4; the disease is breast cancer.